低收入和中等收入国家慢性呼吸系统疾病基本药物的可得性、成本和可负担性：横断面研究

IF 9 1区医学 Q1 RESPIRATORY SYSTEM

Thorax Pub Date : 2024-05-17 DOI:10.1136/thorax-2023-221349

Marie Stolbrink, Obianuju B Ozoh, David M G Halpin, Rebecca Nightingale, Jamilah Meghji, Catherine Plum, Brian William Allwood, Shamanthi Jayasooriya, Kevin Mortimer

{"title":"低收入和中等收入国家慢性呼吸系统疾病基本药物的可得性、成本和可负担性：横断面研究","authors":"Marie Stolbrink, Obianuju B Ozoh, David M G Halpin, Rebecca Nightingale, Jamilah Meghji, Catherine Plum, Brian William Allwood, Shamanthi Jayasooriya, Kevin Mortimer","doi":"10.1136/thorax-2023-221349","DOIUrl":null,"url":null,"abstract":"Contemporary data on the availability, cost and affordability of essential medicines for chronic respiratory diseases (CRDs) across low-income and middle-income countries (LMICs) are missing, despite most people with CRDs living in LMICs. Cross-sectional data for seven CRD medicines in pharmacies, healthcare facilities and central medicine stores were collected from 60 LMICs in 2022–2023. Medicines for symptomatic relief were widely available and affordable, while preventative treatments varied widely in cost, were less available and largely unaffordable. There is an urgent need to address these issues if the Sustainable Development Goal 3 is to be achieved for people with asthma by 2030.","PeriodicalId":23284,"journal":{"name":"Thorax","volume":null,"pages":null},"PeriodicalIF":9.0000,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Availability, cost and affordability of essential medicines for chronic respiratory diseases in low-income and middle-income countries: a cross-sectional study\",\"authors\":\"Marie Stolbrink, Obianuju B Ozoh, David M G Halpin, Rebecca Nightingale, Jamilah Meghji, Catherine Plum, Brian William Allwood, Shamanthi Jayasooriya, Kevin Mortimer\",\"doi\":\"10.1136/thorax-2023-221349\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Contemporary data on the availability, cost and affordability of essential medicines for chronic respiratory diseases (CRDs) across low-income and middle-income countries (LMICs) are missing, despite most people with CRDs living in LMICs. Cross-sectional data for seven CRD medicines in pharmacies, healthcare facilities and central medicine stores were collected from 60 LMICs in 2022–2023. Medicines for symptomatic relief were widely available and affordable, while preventative treatments varied widely in cost, were less available and largely unaffordable. There is an urgent need to address these issues if the Sustainable Development Goal 3 is to be achieved for people with asthma by 2030.\",\"PeriodicalId\":23284,\"journal\":{\"name\":\"Thorax\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":9.0000,\"publicationDate\":\"2024-05-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Thorax\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/thorax-2023-221349\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thorax","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/thorax-2023-221349","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

摘要

尽管大多数慢性呼吸系统疾病（CRD）患者生活在低收入和中等收入国家（LMIC），但有关这些国家慢性呼吸系统疾病（CRD）基本药物的可用性、成本和可负担性的当代数据却很缺乏。2022-2023 年，我们在 60 个低收入和中等收入国家收集了药房、医疗机构和中央药库中七种 CRD 药物的横截面数据。用于缓解症状的药物供应广泛且价格低廉，而预防性治疗药物的成本差异很大，供应较少且大多负担不起。如果要在 2030 年之前为哮喘患者实现可持续发展目标 3，就迫切需要解决这些问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Availability, cost and affordability of essential medicines for chronic respiratory diseases in low-income and middle-income countries: a cross-sectional study

Contemporary data on the availability, cost and affordability of essential medicines for chronic respiratory diseases (CRDs) across low-income and middle-income countries (LMICs) are missing, despite most people with CRDs living in LMICs. Cross-sectional data for seven CRD medicines in pharmacies, healthcare facilities and central medicine stores were collected from 60 LMICs in 2022–2023. Medicines for symptomatic relief were widely available and affordable, while preventative treatments varied widely in cost, were less available and largely unaffordable. There is an urgent need to address these issues if the Sustainable Development Goal 3 is to be achieved for people with asthma by 2030.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Thorax 医学-呼吸系统

CiteScore

16.10

自引率

2.00%

发文量

197

审稿时长

1 months

期刊介绍： Thorax stands as one of the premier respiratory medicine journals globally, featuring clinical and experimental research articles spanning respiratory medicine, pediatrics, immunology, pharmacology, pathology, and surgery. The journal's mission is to publish noteworthy advancements in scientific understanding that are poised to influence clinical practice significantly. This encompasses articles delving into basic and translational mechanisms applicable to clinical material, covering areas such as cell and molecular biology, genetics, epidemiology, and immunology.